Name: Global Epigenetic Therapies for Cancer Market Report, [2035]
Creator: Roots Analysis
Published: 2025-02-14T00:00:01+05:30
License: https://www.rootsanalysis.com/privacy.html
Keywords: Epigenetic Therapies for Cancer Market, Epigenetic Therapies for Cancer Market Growth, Epigenetic Therapies for Cancer Market Trends, Epigenetic Therapies for Cancer Market Size, Epigenetic Therapies for Cancer Market Share, Epigenetic Therapies for Cancer Market Analysis, Epigenetic Therapies for Cancer Market Forecast, Epigenetic Therapies for Cancer Market Report, Global Epigenetic Therapies for Cancer Market, Epigenetic Therapies for Cancer Industry

Epigenetic Therapies for Cancer Market Overview

The global epigenetic therapies for cancer market size, valued at USD 14.32 billion in 2024, is projected to reach USD 16.93 billion in 2025 and USD 66.12 billion by 2035, representing a CAGR of 14.6% during the forecast period.

Epigenetic Therapies for Cancer Market Distribution by Geographical Regions

Epigenetic Therapies for Cancer Market: In Summary

Epigenetic therapies have shown promising results, particularly in hematological cancers like lymphoma and leukemia, by reversing abnormal gene expression patterns without altering the DNA sequence.
Advances in molecular diagnostics / profiling techniques (next-generation sequencing, and liquid biopsies) enable precise identification of epigenetic changes in cancer cells, allowing for the development of targeted epigenetic drugs and biomarker-driven patient selection strategies.
The convergence of epigenomics, genomics, and proteomics data accelerates epigenetic drug discovery by providing a comprehensive understanding of disease mechanisms and enabling the development of highly precise drugs.
In terms of type of therapy, DNA Methyltransferase Inhibitors (DNMTi) currently hold the largest market share due to their proven efficacy in silencing cancer-promoting genes. However, Bromodomain and Extra-Terminal Domain (BET) Inhibitors are anticipated to exhibit a higher CAGR, as they effectively target proteins that regulate gene expression to inhibit cancer cell growth.
Hematological cancers dominate the market, accounting for 60% of the share, largely due to the approval of DNMTi and HDACi drugs for these malignancies. Nevertheless, the solid tumors segment is expected to register a higher CAGR, driven by increasing research and development efforts to target these prevalent cancers.
North America currently holds the largest share (45%) of the epigenetic therapies for cancer market. This dominance is due to robust research activities, ongoing clinical trials for targeted therapies, and strong support from regulatory agencies for next-generation epigenetic cancer drugs. The Asia-Pacific region is projected to experience the fastest growth, primarily fueled by increasing government initiatives and funding to support research and development of advanced epigenetic cancer drugs in the region.
A significant trend is the shift towards combination therapies, integrating epigenetic drugs with immunotherapies to enhance efficacy, overcome drug resistance, and make cancer cells more visible to the immune system. This approach has proven more effective than monotherapy in oncology.
Industrial players, such as Pfizer (US), Merck (US), and GSK (UK) are increasing research initiatives to develop more innovative drugs, which is expected to drive the market in the future.

Epigenetic Therapies for Cancer Market Introduction

Cancer has been a major cause of concern for the healthcare industry, creating immense pressure to develop advanced therapies. As per the latest report of National Institute of Health, in 2025, nearly 2,041,910 cancer cases are projected to occur in the US. To date, several cancer therapeutics has been developed to treat patients and reduce the risk of mortality. Pharmaceutical industry is exploring more innovative therapies, such as epigenetics therapies, to target wide range of cancer.

Notably, epigenetic therapies has shown promising results during various clinical trials, specifically lymphoma and leukemia (form of liquid tumors). These therapies helps to reverse abnormal gene expression patterns within cancerous cells by targeting epigenetic mechanisms. It is important to highlight here that epigenetic therapies helps to restore gene activity mechanism (on / off gene switch) without altering the DNA sequence, specifically silencing cancer-promoting genes.

Unlock Deeper Insights – Schedule Your Personalized Workshop Today!

Several research programs are underway to develop advanced epigenetic therapies for targeting cancer or solid tumors. For instance, in January 2025, a study published in John Hopkins Medicine highlighted that a team of researchers at Johns Hopkins Kimmel Cancer Center and Chinese Academy of Sciences identify new epigenetic approach to target colorectal cancer. During this study, researchers found a mouse protein that disrupts cancer-causing chemicals within genes associated with colorectal cancer cells. This new finding has further triggered research on epigenetics therapies, which is expected to offer lucrative opportunities for innovation and investment in epigenetic therapies for cancer market.

Epigenetic Therapies for Cancer Market: Report Attributes

Key Report Attribute	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 16.93 Billion
Market Size 2035	USD 66.12 Billion
CAGR (Till 2035)	14.6%

One of the key objectives of the epigenetic therapies for cancer market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global epigenetic therapies for cancer market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of therapy, application area, route of administration, end user, geographical regions, and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

Recent Developments in Epigenetic Therapies for Cancer Market

Several recent developments in the field of epigenetic therapies for cancer industry have occurred, and we outlined some of these below.

In April 2025, Pfizer presented updated results from its ongoing Phase I studies that indicates the dosing strategy for two molecules targeting epigenetic regulators: mevrometostat (an investigation EZH2 inhibitor), which is currently being evaluated in combination with XTANDI for metastatic castration-resistant prostate cancer, and PF-07248144 (first-in-class KAT6 inhibitor for ER+ / HER2) for metastatic breast cancer.

In April 2025, a study co-led by the University of Maryland School of Medicine researchers published in Cancer Research identified a 'master regulator' gene, ZNFX1, which act as a biomarker to assist in treatment of patients with therapy resistance ovarian cancer.

In February 2025, a team of scientists (Song, J., Yang, P., Chen, C. et al.) highlighted that targeting epigenetic regulators emerge as a promising solution to overcome cancer therapy resistance.

See What’s in the Full Report – Request Your Complimentary Insights!

Epigenetic Therapies for Cancer Market Segmentation Insights

The market report provides comprehensive information on epigenetic therapies for cancer market players who are currently active across various segments of the industry as mentioned in the table below.

Epigenetic Therapies for Cancer Market: Market Segmentation

Market Segmentation	Details
Type of Therapy	DNA Methyltransferase Inhibitors (DNMTi) Histone Deacetylase Inhibitors (HDACi) Histone Methyltransferase Inhibitors Bromodomain and Extra-Terminal Domain (BET) Inhibitors Others
Application Area	Solid Tumors Hematological Cancers Others
Route of Administration	Oral Subcutaneous Injectables
End User	Hospitals Cancer Research Institutes Specialty Clinics Others
Geographical Regions	North America Europe Asia-Pacific Middle East & Africa Latin America
Market In North America	US Canada Mexico
Market In Europe	France Germany Italy Spain UK Rest of Europe
Market in Asia-Pacific	China India Japan South Korea New Zealand Rest of Asia-Pacific
Market in Middle East & Africa	Egypt Saudi Arabia South Africa United Arab Emirates
Market in Latin America	Argentina Brazil

Industry Experts on Epigenetic Therapies for Cancer Market

The global personalized cancer epigenetic treatments market is gaining traction due to the growing demand for target specific solutions for cancer treatment. Selective BET blockade is redefining the pathway to fix reversible epigenetic in solid tumors.

'There is a tremendous unmet need to develop new approaches to therapeutically block DNA methylation abnormalities to treat patients with solid tumors,' said Stephen Baylin, (M.D., the Virginia and D.K. Ludwig Professor of Oncology and Medicine at Johns Hopkins and co-director of the Johns Hopkins Kimmel Cancer Center Genetics and Epigenetics Program).

Market Share by Type of Therapy: Does DNA methyltransferase Inhibitors Market Expand in the Future?

Based on the type of therapy, the global market is distributed across DNA methyltransferase inhibitors (DNMTi), histone deacetylase inhibitors (HDACi), histone methyltransferase inhibitors, bromodomain and extra-terminal domain (BET) inhibitors, and others. According to epigenetic therapies for cancer market report, the DNA methyltransferase inhibitors segment holds the highest share of the market. This can be attributed to the fact that the DNA methyltransferase inhibitors have shown promising outcomes in the treatment of cancer by silencing the genes in cancer cells.
It is important to highlight that the bromodomain and extra-terminal domain (BET) inhibitors segment is likely to grow at a higher CAGR in the future. This can be ascribed to the fact that BET inhibitors can target the proteins that interact with acetylated histones, that further helps to regulate the gene expression to inhibit the growth of cancer cell.

Have Questions? Let's Get Them Answered

Market Share by Application Area: How HDAC Inhibitors are Transforming Treatment Resistance Patterns in Hematological Malignancies?

The global market is segmented across different application area, such as solid tumors, hematological cancers, and others. Among these, the hematological cancers segment is holding 60% of the cancer epigenetics market share. This can be attributed to the rising approval of the DNA methyltransferase inhibitors (DNMTi), and histone deacetylase inhibitors (HDACi) drugs by the USFDA to treat hematological malignancies.
It is worth noting that the solid tumors segment is anticipated to register higher CAGR during the forecast period. The rising research on epigenetic therapies to target solid tumors is the key driver for unprecedented growth of this segment.

Market Share by Route of Administration: Why Do Injectable Segment Holds the Highest Share?

Based on the route of administration, the global market is segmented into oral, subcutaneous and injectables. According to the epigenetic therapies for cancer market forecast, the injectables segment is dominating the market by holding maximum share. This can be attributed to the fact that injections helps to surpass the gastrointestinal barriers and deliver drug at targeted location for higher efficiency.
Notably, the injectables segment will continue to grow at a higher CAGR in the future. This reflects the higher adoption of injectable mode for delivering epigenetic therapies.

Market Share by End User: Cancer Research Institutes Will Continue to Maintain Its Dominance in the Future

The end user segment highlights the distribution of global market across hospitals, cancer research institutes, specialty clinics, and others. According to the epigenetic therapy for cancer industry analysis, the cancer research institutes segment is dominating the market by securing highest share. This dominance is due to the increasing research on epigenetic therapies to target cancerous cells.
It is important to highlight here that this segment will continue to maintain its dominance and is likely to grow at a higher CAGR during the forecast period. The ongoing research and clinical trials on the epigenetic therapies are likely to be the robust reason for unprecedented growth of this segment.

Market Share by Geographical Regions: How Clinical Trial Outcomes Driving USFDA Approvals For Next-Generation Epigenetic Cancer Drugs in North America?

The global market is distributed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Based on our analysis, currently the North America is accounting for 45% of the epigenetic therapies for cancer market growth. This dominance reflects from the increasing research on epigenetic therapies, ongoing clinical trials on the targeted therapies, and support from the regulatory agencies for next-generation epigenetic cancer drugs.
The market for epigenetic therapy for cancer in Asia-Pacific is expected to grow at a higher CAGR during the forecast period. This immense growth is due to the rising government initiatives to support research on advanced epigenetic cancer drugs.

Epigenetic Therapy for Cancer Market: Report Deliverables

Report Deliverables	Details
Excel Data Packs (Complimentary)	Available
Key Epigenetic Therapy for Cancer Companies Profiled	Abcam (UK) Active Motif (US) Bio-Rad Laboratories (US) Epic Bio (US) Illumina (US) K36 Therapeutics (US) Merck (Germany) New England Biolabs (US) Novartis (Switzerland) Omega Therapeutics (US) Pfizer (US) QIAGEN (Germany) Roche (Switzerland) Syndax Pharmaceuticals (US) Thermo Fisher Scientific (US) (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Epigenetic Therapy for Cancer Market Key Takeaways

The “Epigenetic Therapy for Cancer Market Report: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for epigenetic therapy for cancer industry players. The market research report lays emphasis on the epigenetic therapies that are being developed for the cancer treatment. Key takeaways of the market report are briefly discussed below.

Competitive Landscape: How is the Competitive Landscape Shaping Up Between Big Pharma and Biotech Firms?

The emerging regulatory pathways for epigenetic biomarker-guided cancer treatment selection has catered the attention of industrial players for innovation in this field. Overall, the market for epigenetic therapy for cancer is moderately competitive, featuring the presence of well-established pharmaceutical players and research institutes. Notably, the cancer research institutes, and pharmaceutical industrial players are co-jointly focusing on the development of next-generation epigenetic therapy to treat cancer. As more market players enter into the industry, this market will remain competitive for the long term.

Market Size Analysis: What Makes Combination Epigenetic-Immunotherapy Approaches More Effective Than Monotherapy in Oncology?

In 2025, the epigenetic therapy for cancer market is expected to be valued at USD 16.93 billion. This unprecedented growth is driven by the rising demand for combination epigenetic immunotherapy to treat cancer with higher efficacy. Notably, the combination approach is widely used to mitigate the concern of off-target effects.

Market Drivers: What Factors are Driving the Cancer Epigenetic Therapy Industry?

Epigenetic therapies have shown promising outcomes to treat cancer specifically malignant tumors, which is expected to drive its demand in the future. Several other promising factors that are driving the market growth are listed below:

Rising Demand for Precision Medicine in Oncology: Are Biomarker-Driven Patient Selection Strategies Increasing Adoption Rates?

The rising trend of oncology precision medicine is the key driver for the market. Notably, the availability of advanced molecular profiling techniques, such as next generation sequencing and liquid biopsies helps to identify the genetic mutations, and epigenetic changes that drivers the growth of cancerous cells. These detailed profiling helps to identify targeted epigenetic drugs that precisely target these abnormalities. Additionally, this approach also helps to identify the precision oncology epigenetic biomarkers that allow clinicians to select patients that are benefitted from epigenetic drugs.

Rising Next-Generation Epigenetic Drugs Pipeline: What's the Addressable Market for Next-Generation Epigenetic Drug Classes?

The emergence of novel epigenetic drug targets beyond histone deacetylase inhibitors cancer to target broad range of epigenetic regulators in individual tumors are offering new possibilities for industrial players. Notably, this precision approach helps to develop patient specific next-generation epigenetic drugs to treat cancer. Currently, several epigenetic drugs are being evaluated under clinical trials and researchers are exploring next-generation epigenetic drugs to target tumors which is likely to drive the market in the future.

Market Challenges: What are the Key Challenges in the Market?

High Development Cost of Epigenetic Therapy

Notably, the high cost associated with the development of epigenetic therapy is likely to slow the uptake of drugs in the community. It is worth mentioning that the development of drug require multiple clinical trials, drug study and approval from the regulatory authorities. The entire process may increase the expenses of epigenetic drug development, creating challenges for the market players.

Off-Target Toxicities: How Off-Target Toxicities Create Barriers To Scaling Personalized Epigenetic Therapies In Solid Tumor Treatment?

It is worth noting that when an epigenetic drug inhibits an enzyme that regulates the gene processes (histone deacetylase or DNA methyltransferase), it can affect both cancerous and healthy cells. This off-target toxicity due to lack of target-specificity may lead to undesirable side effects and impact normal cell function. Therefore, the off-target toxicity may create challenges to achieve high therapeutic efficiency.

Future Trends: What are the Top Epigenetic Cancer Drugs Market Trends Shaping the Industrial Growth?

Driven by the ongoing research, several market players are focusing on the emerging trends that are shaping the market growth. Some of the potential opportunities in this industry are listed below:

Increasing Shift Towards Combination Therapies: How do Combination Therapies with Immunotherapy Impact Market Dynamics?

In order to enhance the therapeutic efficacy, several market players are focusing on the development of combination therapies that includes the combination of epigenetics and immunotherapy drugs. This significant combination helps to overcome the cancer drug resistance challenges, specifically when immune checkpoint inhibitors does not respond into patient body. Additionally, the combination of epigenetic inhibitor can induce the expression of neoantigens which makes cancer cells more visible to immune system, thereby killing it. As researchers continue to explore combination therapies, this market is expected to grow dynamically in the future.

Integration of Multi-Omics Studies: Why Multi-Omics Integration Accelerates Epigenetic Drug Discovery Timelines?

The notable shift towards multi-omics integration has significantly accelerates the discovery of epigenetic drugs discovery. Notably, the integration of multi-omics (epigenomics, genomics and proteomics data) allow researcher to identify epigenetic dysregulation in cancer. This comprehensive view helps to understand disease mechanism and develop precise drugs to treat cancer.

Don't Pay for What You Don't Need. Individual Sections of the Report Are Available for Purchase Now.

What are the Top Strategic Moves of the Epigenetic Therapy for Cancer Market Players?

With growing pipeline of epigenetic combination therapy trials under clinical studies, numerous players are actively undertaking strategic initiatives to strengthen the market growth. Some of the notable strategies adopted by the market players are listed below:

Company	Leading Epigenetic Assets	Key Strategic Moves
Ipsen / Epizyme (France)	Tazemetostat (EZH2i)	Sarcoma label expansion, pembrolizumab combo
GSK (UK)	JNJ-64619178 (PRMT5), belinostat HDACi	Multi-omics companion Dx integration to enhance study on epigenomics
Bristol Myers Squibb (US)	CC-90010 (BETi), 5-azacitidine franchise	Fixed-dose azacitidine/cedazuridine oral HMA approved

Epigenetic Therapy for Cancer Market Report Coverage

An Infographic Executive Summary
Regulatory Scenario
Comprehensive Database of Leading Players
Competitive Landscape
Porter’s Five Forces Analysis
Company Competitiveness Analysis
Startup Ecosystem in the Epigenetic Therapy for Cancer Market
Company Profiles
Patent Analysis
Partnerships and Collaborations
Grant Analysis
Funding and Investment Analysis
Clinical Trial Analysis
Market Opportunity Analysis
SWOT Analysis

Glossary

DNMTi (DNA Methyl-Transferase Inhibitors): These are enzymes responsible for adding methyl groups (CH3) to DNA, primarily at cytosine residues within CpG dinucleotides (a cytosine followed by a guanine in the DNA sequence). This process is called DNA methylation.
HDACi (Histone Deacetylase Inhibitor): These are enzymes that remove acetyl groups from lysine residues on proteins, most famously on the N-terminal tails of histone proteins. HDACs are often contrasted with histone acetyltransferases (HATs), which add acetyl groups.
Epigenomic: The epigenome refers to the multitude of chemical compounds and proteins that can attach to DNA and histones (proteins around which DNA is wrapped) and direct actions such as turning genes on or off, controlling the production of proteins in specific cells, and influencing chromatin structure.

From the Author’s Desk

Author’s View on Epigenetic Therapy for Cancer Market

Epigenetic therapy for cancer is a whole new approach to target cancerous cells with a target-specific approach without altering the DNA sequence. This new research has offered dynamic possibilities for the pharmaceutical industry to develop next-generation epigenetic drugs with higher efficacy to treat solid tumors. The next decade will witness epigenetic therapies evolving from niche applications to cornerstone treatments, driven by improved formulations, advanced molecular diagnostics, and groundbreaking technologies. Notably, the technologies like BET-PROTACs and CRISPR epigenome modifiers that are fundamentally reshaping our approach to cancer treatment by precisely manipulating the very software of our cells.

Customization Opportunities

At Roots Analysis, we genuinely care about your success and understand that your business requirements are unique. While our market research reports provide valuable insights, we recognize that they might not cover every aspect you need to make well-informed strategic decisions. To account for that, we offer 15% free report customization tailored to your specific needs. Whether you require additional quantitative analysis, qualitative insights, or any other information related to the electric vehicles market, reach out to us today at support@rootsanalysis.com

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

1.6. Chapter Outlines

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Introduction

2.4.2.2. Types

2.4.2.2.1. Qualitative

2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques

2.4.2.4.1. Interviews

2.4.2.4.2. Surveys

2.4.2.4.3. Focus Groups

2.4.2.4.4. Observational Research

2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders

2.4.2.5.1. Company Executives (CXOs)

2.4.2.5.2. Board of Directors

2.4.2.5.3. Company Presidents and Vice Presidents

2.4.2.5.4. Key Opinion Leaders

2.4.2.5.5. Research and Development Heads

2.4.2.5.6. Technical Experts

2.4.2.5.7. Subject Matter Experts

2.4.2.5.8. Scientists

2.4.2.5.9. Doctors and Other Healthcare Providers

2.4.2.6. Ethics and Integrity

2.4.2.6.1. Research Ethics

2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

+ 3. MARKET DYNAMICS

3.1. Forecast Methodology

3.1.1. Top-Down Approach

3.1.2. Bottom-Up Approach

3.1.3. Hybrid Approach

3.2. Market Assessment Framework

3.2.1. Total Addressable Market (TAM)

3.2.2. Serviceable Addressable Market (SAM)

3.2.3. Serviceable Obtainable Market (SOM)

3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques

3.3.1. Qualitative Forecasting

3.3.2. Correlation

3.3.3. Regression

3.3.4. Time Series Analysis

3.3.5. Extrapolation

3.3.6. Convergence

3.3.7. Forecast Error Analysis

3.3.8. Data Visualization

3.3.9. Scenario Planning

3.3.10. Sensitivity Analysis

3.4. Key Considerations

3.4.1. Demographics

3.4.2. Market Access

3.4.3. Reimbursement Scenarios

3.4.4. Industry Consolidation

3.5. Robust Quality Control

3.6. Key Market Segmentations

3.7. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Overview of Major Currencies Affecting the Market

4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact

4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt

4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Overview of Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product (GDP)

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. R&D Innovation

4.2.11.7. Stock Market Performance

4.2.11.8. Supply Chain

4.2.11.9. Cross-Border Dynamics

+ 5. EXECUTIVE SUMMARY

+ 6. INTRODUCTION

6.1. Chapter Overview

6.2. Overview of Epigenetic Therapy for Cancer

6.2.1. Types of Epigenetic Therapy for Cancer

6.2.2. Mechanism of Action of Epigenetic Therapy for Cancer

6.2.3. Advantages of Epigenetic Therapy for Cancer

6.2.4. Challenges Associated with Epigenetic Therapy for Cancer

6.3. Future Perspective

+ 7. REGULATORY SCENARIO

+ 8. COMPREHENSIVE DATABASE OF LEADING PLAYERS

+ 9. COMPETITIVE LANDSCAPE

9.1. Chapter Overview

9.2. Epigenetic Therapy for Cancer: Overall Market Landscape

9.2.1. Analysis by Year of Establishment

9.2.2. Analysis by Company Size

9.2.3. Analysis by Location of Headquarters

9.2.4. Epigenetic Therapy for Cancer: Overall Market Landscape

9.2.4.1. Analysis by Therapy Type

9.2.4.2. Analysis by Application Area

9.2.4.3. Analysis by Route of Administration

9.2.4.4. Analysis by End User

+ 10. PORTER'S FIVE FORCES ANALYSIS

+ 11. COMPETITIVE COMPETITIVENESS ANALYSIS

+ 12. STARTUP ECOSYSTEM IN THE EPIGENETIC THERAPY FOR CANCER MARKET

12.1. Epigenetic Therapy for Cancer: Market Landscape of Startups

12.1.1. Analysis by Year of Establishment

12.1.2. Analysis by Company Size

12.1.3. Analysis by Company Size and Year of Establishment

12.1.4. Analysis by Location of Headquarters

12.1.5. Analysis by Company Size and Location of Headquarters

12.1.6. Analysis by Ownership Structure

12.2. Key Findings

+ 13. COMPANY PROFILES

13.1. Chapter Overview

13.2. Abcam (UK)

13.2.1. Company Overview

13.2.2. Company Mission

13.2.3. Company Footprint

13.2.4. Management Team

13.2.5. Contact Details

13.2.6. Financial Performance

13.2.7. Operating Business Segments

13.2.8. Pipeline Portfolio

13.2.9. MOAT Analysis

13.2.10. Recent Developments and Future Outlook

* similar detail is presented for other below mentioned companies based on information in the public domain

13.3. Active Motif (US)

13.4. Bio-Rad Laboratories (US)

13.5. Epic Bio (US)

13.6. Illumina (US)

13.7. K36 Therapeutics (US)

13.8. Merck (Germany)

13.9. New England Biolabs (US)

13.10. Novartis (Switzerland)

13.11. Omega Therapeutics (US)

13.12. Pfizer (US)

13.13. QIAGEN (Germany)

13.14. Roche (India)

13.15. Syndax Pharmaceuticals (US)

13.16. Thermo Fisher Scientific (US)

+ 14. PATENT ANALYSIS

14.1. Chapter Overview

14.2. Scope and Methodology

14.3. Epigenetic Therapy for Cancer: Patent Analysis

14.3.1. Analysis by Patent Publication Year

14.3.2. Analysis by Type of Patent and Patent Publication Year

14.3.3. Analysis by Patent Application Year

14.3.4. Analysis by Patent Jurisdiction

14.3.5. Analysis by CPC Symbols

14.3.6. Analysis by Type of Applicant

14.3.7. Leading Industry Players: Analysis by Number of Patents

14.3.8. Leading Individual Assignees: Analysis by Number of Patents

+ 15. PARTNERSHIPS AND COLLABORATIONS

15.1. Chapter Overview

15.2. Partnership Models

15.3. Epigenetic Therapy for Cancer: Partnerships and Collaborations

15.3.1. Analysis by Year of Partnership

15.3.2. Analysis by Type of Partnership

15.3.3. Analysis by Year and Type of Partnership

15.3.4. Analysis by Type of Partner

15.3.5. Analysis by Location of Headquarters of Partner

15.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner

15.3.7. Most Active Players: Analysis by Number of Partnerships

15.3.8. Regional Analysis

15.3.8.1. Intercontinental and Intracontinental Deals

15.3.8.2. Local and International Deals

+ 16. GRANT ANALYSIS

16.1. Chapter Overview

16.2. Scope and Methodology

16.3. Epigenetic Therapy for Cancer: Grant Analysis

16.3.1. Analysis by Year of Grant Award

16.3.2. Analysis by Amount Awarded

16.3.3. Analysis by Support Period

16.3.4. Analysis by Support Period and Funding Institute Center

16.3.5. Analysis by Type of Grant Application

16.3.6. Analysis by Purpose of Grant Award

16.3.7. Analysis By Activity Code

16.3.8. Analysis by NIH Spending Category

16.3.9. Analysis by Study Section Involved

16.3.10. Popular NIH Departments: Analysis by Number of Grants

16.3.11. Analysis by Type of Recipient Organization

16.3.12. Prominent Program Officers: Analysis by Number of Grants

16.3.13. Popular Recipient Organizations: Analysis by Number of Grants

16.3.14. Popular Recipient Organizations: Analysis by Grant Amount

16.3.15. Analysis by Region of Recipient Organizations

+ 17. FUNDING AND INVESTMENTS ANALYSIS

17.1. Funding Models

17.2. Epigenetic Therapy for Cancer: Funding and Investments

17.2.1. Analysis by Year of Funding

17.2.2. Analysis of Funding Instances by Type of Funding

17.2.3. Analysis of Funding Instances by Year and Type of Funding

17.2.4. Analysis of Amount Invested by Type of Funding

17.2.5. Analysis of Funding Instances by Country

17.2.6. Most Active Players: Analysis by Amount Raised

17.3. Summary and Key Takeaways

+ 18. CLINICAL TRIAL ANALYSIS

18.1. Analysis Methodology and Key Parameters

18.2. Epigenetic Therapy for Cancer: Clinical Trial Analysis

18.2.1. Analysis by Trial Status

18.2.2. Analysis by Trial Registration Year

18.2.3. Analysis by Type of Sponsor / Collaborator

18.2.4. Analysis by Type of Study Design

18.2.5. Analysis by Registration Year and Type of Study

18.2.6. Analysis by Patient Enrollment

18.2.7. Year-wise Trend of Completed and Recruiting Trials

18.2.8. Analysis by Age Category

18.2.9. Word Cloud of Study Titles

18.2.10. Most Active Industry Players: Analysis by Number of Registered Trials

18.2.11. Most Active Non- Industry Players: Analysis by Number of Registered Trials

18.2.12. Analysis by Trial Location

18.2.13. Analysis by Trial Status and Geography

+ 19. GLOBAL EPIGENETIC THERAPY FOR CANCER MARKET

19.1. Chapter Overview

19.2. Key Assumptions and Methodology

19.3. Trends Disruption Impacting Market

19.4. Demand Side Trends

19.5. Supply Side Trends

19.6. Global Epigenetic Therapy for Cancer Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.7. Multivariate Scenario Analysis

19.7.1. Conservative Scenario

19.7.2. Optimistic Scenario

19.8. Investment Feasibility Index

19.9. Key Market Segmentations

+ 20. MARKET OPPORTUNITIES BASED ON TYPE OF THERAPY

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. Revenue Shift Analysis

20.4. Market Movement Analysis

20.5. Penetration-Growth (P-G) Matrix

20.6. Epigenetic Therapy for Cancer Market for DNA Methyltransferase Inhibitors (DNMTi): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.7. Epigenetic Therapy for Cancer Market for Histone Deacetylase Inhibitors (HDACi): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.8. Epigenetic Therapy for Cancer Market for Histone Methyltransferase Inhibitors: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.9. Epigenetic Therapy for Cancer Market for Bromodomain and Extra-Terminal Domain (BET) Inhibitors: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.10. Epigenetic Therapy for Cancer Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.11. Data Triangulation and Validation

20.11.1. Secondary Sources

20.11.2. Primary Sources

20.11.3. Statistical Modeling

+ 21. MARKET OPPORTUNITIES BASED ON APPLICATION AREA

21.1. Chapter Overview

21.2. Key Assumptions and Methodology

21.3. Revenue Shift Analysis

21.4. Market Movement Analysis

21.5. Penetration-Growth (P-G) Matrix

21.6. Epigenetic Therapy for Cancer Market for Solid Tumors: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.7. Epigenetic Therapy for Cancer Market for Hematological Cancers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.8. Epigenetic Therapy for Cancer Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.9. Data Triangulation and Validation

21.9.1. Secondary Sources

21.9.2. Primary Sources

21.9.3. Statistical Modeling

+ 22. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION

22.1. Chapter Overview

22.2. Key Assumptions and Methodology

22.3. Revenue Shift Analysis

22.4. Market Movement Analysis

22.5. Penetration-Growth (P-G) Matrix

22.6. Epigenetic Therapy for Cancer Market for Oral Route: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7. Epigenetic Therapy for Cancer Market for Subcutaneous Route: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.8. Epigenetic Therapy for Cancer Market for Injectables: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.9. Data Triangulation and Validation

22.9.1. Secondary Sources

22.9.2. Primary Sources

22.9.3. Statistical Modeling

+ 23. MARKET OPPORTUNITIES BASED ON END USER

23.1. Chapter Overview

23.2. Key Assumptions and Methodology

23.3. Revenue Shift Analysis

23.4. Market Movement Analysis

23.5. Penetration-Growth (P-G) Matrix

23.6. Epigenetic Therapy for Cancer Market for Hospitals: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.7. Epigenetic Therapy for Cancer Market for Cancer Research Institutes: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.8. Epigenetic Therapy for Cancer Market for Specialty Clinics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.9. Epigenetic Therapy for Cancer Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.10. Data Triangulation and Validation

23.10.1. Secondary Sources

23.10.2. Primary Sources

23.10.3. Statistical Modeling

+ 24. MARKET OPPORTUNITIES FOR EPIGENETIC THERAPY FOR CANCER IN NORTH AMERICA

24.1. Chapter Overview

24.2. Key Assumptions and Methodology

24.3. Revenue Shift Analysis

24.4. Market Movement Analysis

24.5. Penetration-Growth (P-G) Matrix

24.6. Epigenetic Therapy for Cancer Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.6.1. Epigenetic Therapy for Cancer Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.6.2. Epigenetic Therapy for Cancer Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.6.3. Epigenetic Therapy for Cancer Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.7. Data Triangulation and Validation

+ 25. MARKET OPPORTUNITIES FOR EPIGENETIC THERAPY FOR CANCER IN EUROPE

25.1. Chapter Overview

25.2. Key Assumptions and Methodology

25.3. Revenue Shift Analysis

25.4. Market Movement Analysis

25.5. Penetration-Growth (P-G) Matrix

25.6. Epigenetic Therapy for Cancer Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.1. Epigenetic Therapy for Cancer Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.2. Epigenetic Therapy for Cancer Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.3. Epigenetic Therapy for Cancer Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.4. Epigenetic Therapy for Cancer Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.5. Epigenetic Therapy for Cancer Market in The UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.6. Epigenetic Therapy for Cancer Market in Rest of the Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.7. Data Triangulation and Validation

+ 26. MARKET OPPORTUNITIES FOR EPIGENETIC THERAPY FOR CANCER IN ASIA-PACIFIC

26.1. Chapter Overview

26.2. Key Assumptions and Methodology

26.3. Revenue Shift Analysis

26.4. Market Movement Analysis

26.5. Penetration-Growth (P-G) Matrix

26.6. Epigenetic Therapy for Cancer Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.1. Epigenetic Therapy for Cancer Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.2. Epigenetic Therapy for Cancer Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.3. Epigenetic Therapy for Cancer Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.4. Epigenetic Therapy for Cancer Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.5. Epigenetic Therapy for Cancer Market in New Zealand: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.6. Epigenetic Therapy for Cancer Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.7. Data Triangulation and Validation

+ 27. MARKET OPPORTUNITIES FOR EPIGENETIC THERAPY FOR CANCER IN MIDDLE EAST AND AFRICA (MEA)

27.1. Chapter Overview

27.2. Key Assumptions and Methodology

27.3. Revenue Shift Analysis

27.4. Market Movement Analysis

27.5. Penetration-Growth (P-G) Matrix

27.6. Epigenetic Therapy for Cancer Market in Middle East and Africa (MEA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.1. Epigenetic Therapy for Cancer Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)

27.6.2. Epigenetic Therapy for Cancer Market in Iran: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)

27.6.3. Epigenetic Therapy for Cancer Market in Iraq: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)

27.6.4. Epigenetic Therapy for Cancer Market in Israel: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)

27.6.5. Epigenetic Therapy for Cancer Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.6. Epigenetic Therapy for Cancer Market in South Africa: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.7. Epigenetic Therapy for Cancer Market in United Arab Emirates: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.7. Data Triangulation and Validation

+ 28. MARKET OPPORTUNITIES FOR EPIGENETIC THERAPY FOR CANCER IN LATIN AMERICA

28.1. Chapter Overview

28.2. Key Assumptions and Methodology

28.3. Revenue Shift Analysis

28.4. Market Movement Analysis

28.5. Penetration-Growth (P-G) Matrix

28.6. Epigenetic Therapy for Cancer Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.1. Epigenetic Therapy for Cancer Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.2. Epigenetic Therapy for Cancer Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.7. Data Triangulation and Validation

+ 29. KEY WINNING STRATEGIES

+ 30. SWOT ANALYSIS

+ 31. ROOTS STRATEGIC RECOMMENDATIONS

+ 32. INSIGHTS FROM PRIMARY RESEARCH

+ 33. REPORT CONCLUSION

+ 34. TABULATED DATA

+ 35. LIST OF COMPANIES AND ORGANIZATIONS

+ 36. CUSTOMIZATION OPPORTUNITIES

+ 37. ROOTS SUBSCRIPTION SERVICES

+ 38. AUTHOR DETAILS

Epigenetic Therapies for Cancer Market

Epigenetic Therapies for Cancer Market Overview

Epigenetic Therapies for Cancer Market: In Summary

Epigenetic Therapies for Cancer Market Introduction

Epigenetic Therapies for Cancer Market: Report Attributes

Recent Developments in Epigenetic Therapies for Cancer Market

Epigenetic Therapies for Cancer Market Segmentation Insights

Epigenetic Therapies for Cancer Market: Market Segmentation

Industry Experts on Epigenetic Therapies for Cancer Market

Market Share by Type of Therapy: Does DNA methyltransferase Inhibitors Market Expand in the Future?

Market Share by Application Area: How HDAC Inhibitors are Transforming Treatment Resistance Patterns in Hematological Malignancies?

Market Share by Route of Administration: Why Do Injectable Segment Holds the Highest Share?

Market Share by End User: Cancer Research Institutes Will Continue to Maintain Its Dominance in the Future

Market Share by Geographical Regions: How Clinical Trial Outcomes Driving USFDA Approvals For Next-Generation Epigenetic Cancer Drugs in North America?

Epigenetic Therapy for Cancer Market: Report Deliverables

Epigenetic Therapy for Cancer Market Key Takeaways

Competitive Landscape: How is the Competitive Landscape Shaping Up Between Big Pharma and Biotech Firms?

Market Size Analysis: What Makes Combination Epigenetic-Immunotherapy Approaches More Effective Than Monotherapy in Oncology?

Market Drivers: What Factors are Driving the Cancer Epigenetic Therapy Industry?

Rising Demand for Precision Medicine in Oncology: Are Biomarker-Driven Patient Selection Strategies Increasing Adoption Rates?

Rising Next-Generation Epigenetic Drugs Pipeline: What's the Addressable Market for Next-Generation Epigenetic Drug Classes?

Market Challenges: What are the Key Challenges in the Market?

High Development Cost of Epigenetic Therapy

Off-Target Toxicities: How Off-Target Toxicities Create Barriers To Scaling Personalized Epigenetic Therapies In Solid Tumor Treatment?

Future Trends: What are the Top Epigenetic Cancer Drugs Market Trends Shaping the Industrial Growth?

Increasing Shift Towards Combination Therapies: How do Combination Therapies with Immunotherapy Impact Market Dynamics?

Integration of Multi-Omics Studies: Why Multi-Omics Integration Accelerates Epigenetic Drug Discovery Timelines?

What are the Top Strategic Moves of the Epigenetic Therapy for Cancer Market Players?

Epigenetic Therapy for Cancer Market Report Coverage

Glossary

From the Author’s Desk

Author’s View on Epigenetic Therapy for Cancer Market

Customization Opportunities

Table of Contents

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment

Epigenetic Therapies for Cancer Market

Epigenetic Therapies for Cancer Market Overview

Epigenetic Therapies for Cancer Market: In Summary

Epigenetic Therapies for Cancer Market Introduction

Epigenetic Therapies for Cancer Market: Report Attributes

Recent Developments in Epigenetic Therapies for Cancer Market

Epigenetic Therapies for Cancer Market Segmentation Insights

Epigenetic Therapies for Cancer Market: Market Segmentation

Industry Experts on Epigenetic Therapies for Cancer Market

Epigenetic Therapies for Cancer Market Share Insights

Market Share by Type of Therapy: Does DNA methyltransferase Inhibitors Market Expand in the Future?

Market Share by Application Area: How HDAC Inhibitors are Transforming Treatment Resistance Patterns in Hematological Malignancies?

Market Share by Route of Administration: Why Do Injectable Segment Holds the Highest Share?

Market Share by End User: Cancer Research Institutes Will Continue to Maintain Its Dominance in the Future

Market Share by Geographical Regions: How Clinical Trial Outcomes Driving USFDA Approvals For Next-Generation Epigenetic Cancer Drugs in North America?

Epigenetic Therapy for Cancer Market: Report Deliverables

Epigenetic Therapy for Cancer Market Key Takeaways

Competitive Landscape: How is the Competitive Landscape Shaping Up Between Big Pharma and Biotech Firms?

Market Size Analysis: What Makes Combination Epigenetic-Immunotherapy Approaches More Effective Than Monotherapy in Oncology?

Market Drivers: What Factors are Driving the Cancer Epigenetic Therapy Industry?

Rising Demand for Precision Medicine in Oncology: Are Biomarker-Driven Patient Selection Strategies Increasing Adoption Rates?

Rising Next-Generation Epigenetic Drugs Pipeline: What's the Addressable Market for Next-Generation Epigenetic Drug Classes?

Market Challenges: What are the Key Challenges in the Market?

High Development Cost of Epigenetic Therapy

Off-Target Toxicities: How Off-Target Toxicities Create Barriers To Scaling Personalized Epigenetic Therapies In Solid Tumor Treatment?

Future Trends: What are the Top Epigenetic Cancer Drugs Market Trends Shaping the Industrial Growth?

Increasing Shift Towards Combination Therapies: How do Combination Therapies with Immunotherapy Impact Market Dynamics?

Integration of Multi-Omics Studies: Why Multi-Omics Integration Accelerates Epigenetic Drug Discovery Timelines?

What are the Top Strategic Moves of the Epigenetic Therapy for Cancer Market Players?

Epigenetic Therapy for Cancer Market Report Coverage

Glossary

From the Author’s Desk

Author’s View on Epigenetic Therapy for Cancer Market

Customization Opportunities

Table of Contents

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment